Results 51 to 60 of about 20,060 (180)
Gut and Liver, 2007 Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with ...
doaj +1 more source
Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function
Lung India, 2016 Pulmonary toxicity related to the use of pegylated interferon alpha-2a during treatment of hepatitis C infections is rare; nonetheless, some cases with fatal outcomes have been reported.
Arturo Cortés-Telles
doaj +1 more source
Precision Radiation Oncology, EarlyView.There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang +7 more
wiley +1 more source
PLoS ONE, 2016 BackgroundHepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylated ...
Ran Chen +4 more
doaj +1 more source
Journal of Medical Case Reports, 2012 Introduction The combination of polyethylene glycol (PEG)ylated interferon (pegylated interferon) and ribavirin has been shown to be an effective treatment for chronic hepatitis C virus. In general, common side effects related to this combination therapy
Lahbabi Mounia +4 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Journal of Medical Case Reports, 2010 Introduction Hepatitis-associated aplastic anemia is a common syndrome in patients with bone marrow failure. However, hepatitis-associated aplastic anemia is an immune-mediated disease that does not appear to be caused by any of the known hepatitis ...
Ioannou Savvas +3 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger +14 more
wiley +1 more source
Arquivos de Gastroenterologia, 2004 AIM: Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C.
Elson V. Martins Jr., Ana K. Gaburri
doaj +1 more source
Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
Hepatology Research, EarlyView.Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa +2 more
wiley +1 more source